Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NSCLC
Biotech
AstraZeneca's ph. 3 cancer fail is latest blow to ATR inhibitors
The failure is another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs.
Nick Paul Taylor
Dec 22, 2025 4:35am
Bayer picks Kumquat for $1.3B KRAS collaboration
Aug 12, 2025 6:29am
At ASCO, execs see chance to ‘rewrite textbooks’ in cancer care
Jun 2, 2025 9:45am
Boehringer flexes staying power of HER2-mutant lung cancer med
Apr 28, 2025 9:00am
iTeos drops one of 3 clinical assets from pipeline
Dec 12, 2024 3:10pm
FDA approves Novocure’s tumor field therapy for metastatic NSCLC
Oct 16, 2024 10:14am
